# Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

> **NCT00051103** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline**

## Conditions studied

- Metastatic Breast Cancer
- Neoplasms, Breast

## Interventions

- **DRUG:** Investigational Cancer Drug

## Key facts

- **NCT ID:** NCT00051103
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051103, "Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00051103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*